Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James D Chambers

Showing results (51-60 of 92) with videos related to

Pageof 10
Sort By:
Journal of Psoriasis and Psoriatic Arthritis|September 19, 2024
Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis by Commercial Insurance CompaniesChristine Learned, Sara Alsukait, Kristin R Fiumara, et al.
International Journal of Technology Assessment in Health Care|January 12, 2016
CHANGING FACE OF MEDICARE'S NATIONAL COVERAGE DETERMINATIONS FOR TECHNOLOGYJames D Chambers, Matthew D Chenoweth, Junhee Pyo, et al.
Applied Health Economics and Health Policy|November 25, 2021
Are Medical Devices Cost-Effective?James D Chambers, Madison C Silver, Flora C Berklein, et al.
The American Journal of Managed Care|October 18, 2019
Variation in US private health plans' coverage of orphan drugsJames D Chambers, Ari D Panzer, David D Kim, et al.
Health Affairs (Project Hope)|November 4, 2024
Small-Molecule Drugs Offer Comparable Health Benefits To Biologics At Lower CostsKatherine A Clifford, A Alex Levine, Daniel E Enright, et al.
Health Affairs (Project Hope)|November 5, 2019
Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug CoverageJames D Chambers, Ari D Panzer, Elle F Pope, et al.
Health Affairs Scholar|February 25, 2026
FDA approvals of specialty drugs, 2000-2024Sophie E Knox, Claire H Brennan, Daniel E Enright, et al.
Health Affairs Scholar|July 28, 2025
What drug characteristics explain the wide range of manufacturer rebates?Molly T Beinfeld, Fariel LaMountain, Glenn Phillips, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 2, 2024
The Health Benefits, Costs, and Cost-Effectiveness of Ultraorphan DrugsKatherine A Clifford, A Alex Levine, Daniel E Enright, et al.
Pharmacoepidemiology and Drug Safety|March 27, 2020
What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?Ari D Panzer, Nikoletta M Margaretos, Rachel C Lai, et al.
Pageof 10

Showing results (51-60 of 92) with videos related to

Sort By:
Pageof 10
Journal of Psoriasis and Psoriatic Arthritis|September 19, 2024
Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis by Commercial Insurance CompaniesChristine Learned, Sara Alsukait, Kristin R Fiumara, et al.
International Journal of Technology Assessment in Health Care|January 12, 2016
CHANGING FACE OF MEDICARE'S NATIONAL COVERAGE DETERMINATIONS FOR TECHNOLOGYJames D Chambers, Matthew D Chenoweth, Junhee Pyo, et al.
Applied Health Economics and Health Policy|November 25, 2021
Are Medical Devices Cost-Effective?James D Chambers, Madison C Silver, Flora C Berklein, et al.
The American Journal of Managed Care|October 18, 2019
Variation in US private health plans' coverage of orphan drugsJames D Chambers, Ari D Panzer, David D Kim, et al.
Health Affairs (Project Hope)|November 4, 2024
Small-Molecule Drugs Offer Comparable Health Benefits To Biologics At Lower CostsKatherine A Clifford, A Alex Levine, Daniel E Enright, et al.
Health Affairs (Project Hope)|November 5, 2019
Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug CoverageJames D Chambers, Ari D Panzer, Elle F Pope, et al.
Health Affairs Scholar|February 25, 2026
FDA approvals of specialty drugs, 2000-2024Sophie E Knox, Claire H Brennan, Daniel E Enright, et al.
Health Affairs Scholar|July 28, 2025
What drug characteristics explain the wide range of manufacturer rebates?Molly T Beinfeld, Fariel LaMountain, Glenn Phillips, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 2, 2024
The Health Benefits, Costs, and Cost-Effectiveness of Ultraorphan DrugsKatherine A Clifford, A Alex Levine, Daniel E Enright, et al.
Pharmacoepidemiology and Drug Safety|March 27, 2020
What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?Ari D Panzer, Nikoletta M Margaretos, Rachel C Lai, et al.
Pageof 10